Cat.No. : CSC-RK0018
Host Cell: HeLa Validation: Real-Time RCR
| Cat. No. | CSC-RK0018 |
| Gene | PARP1 |
| Alias | PARP1, PPOL, ADPRT, ADPRT1, PARP-1, ADPRT 1, pADPRT-1 |
| Host Cell | HeLa |
| Host Cell Species | Homo sapiens (Human) |
| Morphology | Epithelial |
| Stability | Validated for at least 10 passages |
| Application | (1) Studying gene functions (2) Studying gene interactions and signaling pathways (3) Target validation and drug discovery (4) Designing diseases models |
| Size Form | >1 × 10^6 cells / vial |
| Shipping | Dry ice |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
The multifunctional nuclear protein poly (ADP-ribose) polymerase 1 (PARP1), also known as ADP-ribosyl transferase 1, is a member of the PARP protein family. The relationship between PARP1 and RNA, namely in alternative splicing, was the focus of the researchers' demonstration of the function of the Human PARP1 Knockdown Cell Line-HeLa in RNA regulation. They found PARP1-RNA binding peaks on mRNA, mostly in intronic regions, using PAR-CLIP. When binding upstream or downstream of skipped exons, PARP1 promotes inclusion; when it is within exons or closer to skipped areas, it promotes skipping. PARP1 prefers GC-rich sequences and modulates exon-skipping events. Truncation mutants demonstrated how the absence of the Zn1Zn2 domain caused PARP1 to switch from binding DNA to RNA, underscoring PARP1's recently discovered function in RNA control.
Figure 1. The researchers demonstrate the impact of Human PARP1 Knockdown Cell Line-HeLa, highlighting altered transcriptional and splicing regulation. PARP1 knockdown in HeLa cells was achieved using ON-TARGETplus Human PARP1 siRNAs and DharmaFECT 1 transfection reagent, followed by an analysis of mRNA or protein levels to confirm knockdown efficiency in seven independent experiments. (Melikishvili M, et al., 2017)
A: The Human PARP1 Knockdown Cell Line-HeLa is generated by using CRISPR/Cas9 gene editing technology, where specific sgRNA fragments are designed and constructed into the CRISPR-U™ vector. These vectors are then transfected into HeLa cells via electroporation or viral infection. Single clones are prepared using the limiting dilution method, and the genotype is confirmed through nucleic acid lysis and PCR amplification with the EZ-editor™ monoclonal genotype identification kit, followed by Sanger sequencing to ensure successful knockout of the PARP1 gene.
A: The Human PARP1 Knockdown Cell Line-HeLa can be used to study the role of PARP1 in cell cycle regulation, particularly during mitosis. By observing the response of cells to mitotic inhibitors after PARP1 knockout, researchers can uncover the critical role of PARP1 in maintaining normal cell cycle progression and chromosome stability.
A: The Human PARP1 Knockdown Cell Line-HeLa provides a platform for studying the role of PARP1 in DNA damage repair, particularly in base excision repair and homologous recombination. With this cell line, scientists can explore how PARP1 participates in the recognition, repair, and signaling processes of DNA damage.
A: The Human PARP1 Knockdown Cell Line-HeLa has significant value in cancer therapy research, especially in developing targeted treatment strategies against PARP1. This cell line can help scientists understand how PARP1 inhibitors affect the growth and survival of cancer cells, providing new perspectives for cancer treatment.
A: The Human PARP1 Knockdown Cell Line-HeLa can be used to study the role of PARP1 in cellular stress responses, such as during oxidative stress or DNA damage. This cell line helps scientists understand how PARP1 participates in cellular stress responses and how these responses affect cell survival and death.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human PARP1 Knockdown Cell Line-HeLa uses precise CRISPR/Cas9 or siRNA technology to knock down the PARP1 gene, ensuring high specificity and reproducibility of experimental results. This precision helps researchers understand the role of PARP1 in cell repair and death, providing therapeutic targets for related diseases.
Using the Human PARP1 Knockdown Cell Line-HeLa allows direct experimentation without the need to construct knockdown models yourself, significantly saving time and costs in preliminary experimental design and preparation. This is crucial for accelerating research progress and reducing research costs.
Since the Human PARP1 Knockdown Cell Line-HeLa is optimized, researchers can directly use these cells for their studies, thus improving the efficiency and smoothness of the experimental process. This efficiency is particularly important for research projects with tight deadlines.
Given the widespread use and acceptance of HeLa cells, the Human PARP1 Knockdown Cell Line-HeLa can be widely applied in various biomedical research fields, including cancer research, genetics studies, etc. Its applicability enhances the breadth and depth of research.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
